Thetis Pharmaceuticals, LLC
Publicly observedDeep River, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Deep River | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Thetis Pharmaceuticals, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | QBDWD3M7YKM9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of TP-317 for Ulcerative Colitis
USD 669,925.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant2 Jun 2023Publicly observed
NIH SBIR/STTR award: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer
USD 271,378.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant2 Jun 2023Publicly observed
NIH SBIR/STTR award: Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer
USD 1,725,203.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant18 Sept 2017Publicly observed
NIH SBIR/STTR award: Development of TP-317 in Ulcerative Colitis
USD 999,696.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.